Zoetis Inc., an animal health company based in Parsippany, has announced an agreement to acquire the animal genomics business of Neogen Corporation for $160 million. The transaction is pending customary closing adjustments and regulatory approvals, with completion expected in the second half of 2026.
Neogen’s genomics division operates five laboratories located in the United States, Brazil, Australia, China, and the United Kingdom, and also maintains an office in Canada. This business provides genotyping platforms that use fixed array and sequencing technologies, along with software solutions designed to help customers make informed decisions about animal health and productivity. Neogen is recognized as a leader in U.S. beef and dairy genomics.
According to Zoetis, integrating Neogen’s genomic technologies will enhance its ability to deliver predictive insights and individualized care across major livestock and companion animal species. The acquisition supports Zoetis’ broader strategy of advancing its Precision Animal Health portfolio and offering greater value to livestock producers globally.
Jamie Brannan, chief commercial officer at Zoetis, said: “The addition of Neogen’s genomics business strengthens our commitment to advancing animal health through innovation, data, and technology. As we continue to grow our leading innovative solutions in Precision Animal Health, this acquisition brings complementary capabilities that expand predictive insights and individualized care, enabling us to deliver added value to customers. Together, we are shaping the future of animal health, empowering customers with the tools they need to support healthier animals and sustainable livestock production globally.”
The deal remains subject to standard closing conditions and regulatory review before it can be finalized.
